Lipocine (NASDAQ:LPCN) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Lipocine Inc. (NASDAQ:LPCN)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.17 and traded as low as $4.96. Lipocine shares last traded at $5.23, with a volume of 24,592 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. StockNews.com assumed coverage on shares of Lipocine in a research report on Thursday. They set a “hold” rating on the stock. Alliance Global Partners initiated coverage on shares of Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price on the stock.

Lipocine Stock Down 1.1 %

The company has a fifty day moving average price of $5.03 and a 200 day moving average price of $5.17. The stock has a market cap of $27.97 million, a PE ratio of -6.88 and a beta of 1.23.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, research analysts predict that Lipocine Inc. will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.